Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07626515
PHASE1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants

Sponsor: Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI) ≥23.0 kilograms per meter squared (kg/m\^2).

Official title: A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Enicepatide in Adult Chinese Participants With Body Mass Index ≥23.0 kg/m2

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2026-07-02

Completion Date

2027-05-14

Last Updated

2026-10-06

Healthy Volunteers

Yes

Interventions

COMBINATION_PRODUCT

Enicepatide

Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.

COMBINATION_PRODUCT

Placebo

Participants will receive matching placebo via subcutaneous (SC) injection as per the schedule in the protocol.

Locations (1)

Peking University First Hospital

Beijing, China